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Previous Gestational Diabetes Mellitus (pGDM) is a common condition and has been associated with future development of Type
2 Diabetes Mellitus (T2DM) and Metabolic Syndrome (MS) in women aﬀected. The pathogenesis and risk factors implicated
in the development of these conditions later in the lives of women with pGDM are not as yet fully understood. Research has
recentlyfocusedonagroupofsubstancesproducedmainlybyadiposetissuecalledadipokines,thisgroupincluding,amongothers,
adiponectin, leptin, Retinol-Binding Protein-4 (RBP-4), and resistin. These substances as well as other inﬂammatory mediators
(CRP,IL-6, PAI-1,TNF-α) seem to play an important role in glucose tolerance and insulin sensitivity dysregulation in women with
pGDM. We summarize the data available on the role of these molecules.
1.Introduction
Pregnancy is a progressively hyperglycemic period of life,
accompanied by increasing insulin resistance as from mid-
gestation, with the hyperglycemia serving a highly important
role in the nutrition and development of the fetus by pro-
viding it with adequate levels of glucose [1].
Gestational Diabetes Mellitus is a common pathologic
statethatincreasestheincidenceofcomplicationsinboththe
motherandthefetus[2].Furthermore,GDMandgestational
dysregulation of blood glucose levels expose the women
aﬀected to higher risk for subsequent development of type
2 diabetes mellitus and cardiovascular disease later in their
lives [3–5], the risk being proportional to the degree of the
dysregulation.
G l u c o s et o l e r a n c ea n dm e t a b o l i s ma sw e l la si n s u l i nr e -
sistance are altered in Type II Diabetes Mellitus (T2DM),
Gestational Diabetes Mellitus (GDM), and the postpartum
period of a pregnancy complicated by pGDM. T2DM and
pGDM have the same predisposing factors, namely, high
body mass index before pregnancy, elevated levels of fasting
glucose, and a degree of hyperglycemia in pregnancy, these
leading to dysglycemia 1 to 4 months after delivery and re-
current gestational diabetes mellitus [6–26].
Although the pathophysiologic mechanisms responsible
for these changes are not as yet completely understood,
growing insight into the processes involved has been gained
over the last few years. There are two main pathways leading
to GDM, T2DM, and possibly pGDM: insulin resistance and
chronic subclinical inﬂammation.
Insulin resistance is caused by the inability of tissues to
respond to insulin and the deﬁcient secretion of insulin by
pancreatic beta cells [27–29]. The deﬁcient secretion cannot
compensate for the pregnancy-induced insulin resistance,2 International Journal of Endocrinology
this resulting in GDM, a condition which sometimes persists
after delivery [8–12, 30].
With regard to the contribution of inﬂammatory pro-
cesses to the pathogenesis of dysglycemia conditions, it
has been reported that long-term activation of the acute
phase inﬂammatory response is a risk factor for T2DM and
cardiovascular disease [31].
Furthermore, obesity has a role in the development of
both T2DM and GDM through chronic subclinical inﬂam-
mation, low-grade activation of the acute phase response,
and dysregulation of adipokines [31–33]. Increased levels of
inﬂammatory agents during and after pregnancy have been
reported in patients with GDM, while increased body fat has
been strongly associated with inﬂammation and adipocyte
necrosis, hypoxia, and release of chemokines which cause
macrophages to inﬁltrate adipose tissue. Macrophages
secrete cytokines which activate the subsequent secretion
of inﬂammation mediating agents, speciﬁcally interleukin-
6 (IL-6) and C-reactive protein (CRP). Moreover, other
molecules such as Plasminogen Activator Inhibitor 1 (PAI-1)
and sialic acid lead to dysregulations of metabolism, hyper-
glycemia, insulin resistance, and, ﬁnally, overt T2DM [31,
34–46].
Crucially, hormones produced by the placenta [47]a n d
increased maternal fat mass [48]h a v eb e e nr e p o r t e dt o
play a major role in GDM. In this context, the gaps in the
mechanisms underlying glucose metabolism in pregnancy
and nonpregnancy states have initiated research eﬀorts to
uncover other potential mediators of insulin resistance,
namely, the adipokines. These are a group of substances,
knowledge about which is continuously expanding, that are
produced mainly in the adipose tissue [49]. The group
includes leptin, adiponectin, tumor necrosis factor alpha
(TNF-α), retinol-binding protein-4 (RBP-4), resistin, vis-
fatin, and apelin. These molecules are involved in a wide
range of physiological processes including lipid metabolism,
atherosclerosis, blood pressure regulation, insulin sensitiv-
ity, and angiogenesis, while they also inﬂuence immunity
and inﬂammation. Their levels in pathologic states appear
increased, with the exception of adiponectin which shows
decreased levels.
Inthispaperwesummarizethedataavailableconcerning
the role of these mediators in women with pGDM.
2.Adipokines inpGDM
Adipokines, whose signiﬁcant role in the pathogenesis of nu-
merous pathologic conditions has recently been recognized,
are adipose tissue-derived substances mediating communi-
cation and endocrine function between this metabolically
activetissueandothersitesthroughoutthebody.Asummary
ofthelevelsofadipokinesandotherinﬂammatorymediators
in cases of pGDM is shown in Table 1.
2.1. Adiponectin. Adiponectin, a well-studied protein, is
secreted by adipose tissue. It has insulin-sensitizing action,
stimulating glucose uptake in skeletal muscle, and reduces
hepatic glucose production through AMP-activated protein
kinase [50], while it also possesses antiatherogenic and anti-
inﬂammatory properties [51, 52]. The levels of adiponectin
decrease as visceral fat increases [53–56] in such conditions
as central obesity, insulin resistance, and diabetes mellitus;
lower adiponectin levels have notably been associated with
subclinical inﬂammation [43]. It has been shown that
adiponectin levels begin to decrease early in the pathogenesis
of diabetes, as adipose tissue increases in tandem with re-
ductionininsulinsensitivity[57].Hypoadiponectinemiahas
alsobeenassociatedwithbetacelldysfunction[58,59],while
it has additionally been linked to future development of
insulin resistance [60] and type 2 diabetes mellitus [61–64],
in the development of which adiponectin appears to have a
causative role.
Adiponectin hasalso been studied in animal experiments
in which it was demonstrated that it can reduce insulin re-
sistance and enhance the action of insulin in liver, resulting
in lowering of glucose blood levels [65–67]. In normal
human pregnancy, adiponectin levels have been found to be
unchanged or decreased [68–72] and negatively correlated
with maternal BMI and insulin sensitivity [73].
In GDM pregnancies adiponectin appears to be de-
creased independently of maternal body mass index (BMI)
or insulin sensitivity [68, 74–85]. Additionally, the fact that
low circulating levels of adiponectin are found early in preg-
nancy has been associated with subsequent development of
GDM [81]. Meanwhile, low levels of adiponectin in preg-
nancy, which have incidentally been associated with certain
ethnic groups such as women of South Asian origin, have a
signiﬁcant impact on the development of GDM [86–88].
While hypoadiponectinemia is strongly associated with
beta-cell dysfunction in pregnancy [89], the levels of
adiponectin after delivery have been investigated in only
a few studies. In one of them the investigators measured
adiponectin levels in 89 women with pGDM at both 3 and
12 months postpartum and compared the values obtained
with normal controls (women with normal pregnancies).
They found that adiponectin levels were lower in women
with pGDM at 3 months postpartum [43]. This registered
decreaseremainsvalidevenaftercorrectionforbodyfatmass
(BFM). The lower values of adiponectin are also associated
with decreased insulin sensitivity and low HDL. It is of note
that plasma adiponectin further decreased by 10% after 1
year in insulin-resistant women with pGDM.
Other investigators [90] studying 25 women with pGDM
and comparing their adiponectin levels with those of 23
women with normal pregnancies at least 1 year after the
index pregnancy (mean 4 years) found that the levels were
signiﬁcantly lower in women with pGDM compared to
normal controls. The diﬀerence remained signiﬁcant even
after adjustment for BMI. This study also showed that
adiponectin was negatively correlated to other inﬂammatory
markers, namely, CRP, PAI-1, and IL-6, the which correla-
tions remained unchanged even after adjustment for BMI.
In another study, 140 women with previous GDM and
various states of glucose tolerance after delivery (8 with
diabetes mellitus, 60 with impaired glucose tolerance and
72 with normal glucose tolerance) were studied and com-
pared with 17 women with normal pregnancies [91].International Journal of Endocrinology 3
Table 1: Adipokines and other inﬂammatory mediators in normal pregnancy, obesity/DM, GDM, and pGDM.
Pregnancy Obesity/DM GDM pGDM
Adiponectin [43, 50–92] Decreased
Unaltered Decreased Decreased Decreased



















Visfatin [139–154] Increased Increased Increased ?
CRP [31, 34–36, 40–46, 90, 155–161] Increased Increased Increased Increased
PAI-1 [31, 34–36, 42, 43, 98, 162] Increased Increased Increased Increased
IL-6 [98, 163–167] Increased Increased Increased Increased
TNF-α [43, 84, 100, 103, 104, 155, 163–167] Increased Increased Increased Increased
The authors reported lower adiponectin levels in the women
with pGDM 1.57 years postdelivery, while it is also of interest
that the levels of adiponectin were progressively lower, the
postpartum glucose tolerance values ranging from normality
to impaired glucose tolerance and ﬁnally Diabetes Mellitus
after GDM (P for linearity = 0.006). Plasma adiponectin was
moreover negatively correlated with fasting glucose, fasting
insulin, and RBP-4 levels.
Another recent study examined 60 women with GDM at
30 weeks of gestation and 6 weeks and 6 months postpartum
and compared the results with normal pregnancies [92].
They did not ﬁnd signiﬁcantly diﬀerent levels of adiponectin
during and after pregnancy in the group of GDM women,
but they did observe a signiﬁcant diﬀerence in the group
of non-GDM women (both at 6 weeks and 6 months
postpartum, P<0.01).
2.2. Leptin. Leptin is an adipokine that is produced by the
ob (obese) gene in adipose tissue cells, especially in white
adipose tissue, its action at the hypothalamus resulting in
decreasing food intake and increasing energy consumption
[93, 94]. It also regulates endocrine function, inﬂammation,
immune response, and angiogenesis.
Its mechanism of action is to increase insulin sensitivity
byinﬂuencing insulin secretion, glucoseutilization, glycogen
synthesis, and fatty acid metabolism [93–95]. Furthermore,
it adjusts gonadotropin releasing-hormone secretion from
the hypothalamus and activates the sympathetic nervous
system.
In normal pregnancy, leptin concentration increases
from early pregnancy onwards and decreases to normal pre-
pregnancy levels before delivery [96–99]. This initial increase
may be due to placental synthesis, since it occurs before the
rise in maternal BMI and rapidly falls after delivery [99].
The function of increased maternal leptin is to enhance the
mobilization of maternal fat stores thus enabling access of
lipid substrates to the fetus [100].
In GDM, leptin has a more debatable role, since it ap-
p e a r st ob ee l e v a t e di nw o m e nw i t hG D M[ 101–103]b u t ,
after adjustment for BMI and insulin resistance [104, 105],
it is shown to be decreased or even unaltered [102], while it
has also been associated with insulin resistance in pregnancy
[101, 103, 105].
T h e r ei st od a t ea ni n s u ﬃc i e n tn u m b e ro fs t u d i e se x a m -
ining the role of leptin in the postpartum period following a
GDM pregnancy. In one study, 89 women with pGDM were
followed and found to have signiﬁcantly increased plasma
leptin at 3 months after delivery (P<0.003) compared to
controls [43]. Leptin levels were negatively associated with
adiponectin but this association was not signiﬁcant after the
adjustment for BFM. Meanwhile, other authors have failed
to ﬁnd any diﬀerence in leptin levels between pGDM and
normal pregnancies 18 months after delivery [91].
Leptin levels were studied [92] during pregnancy and
6 weeks and 6 months after delivery both in normal
pregnancies and in pregnancies complicated by GDM. There
were signiﬁcantly higher levels of leptin in previous GDM
pregnancies compared with normal pregnancies both at 6
weeks and 6 months postpartum.
2.3. Retinol-Binding Protein-4. RBP-4, which is an adipokine
synthesized in hepatocytes and adipocytes, serves as a carrier
for retinol in blood and is postulated to play a role in
regulating glucose metabolism and insulin sensitivity [122,
123].
In pathologic glucose tolerance states (such as obesity,
insulin resistance, polycystic ovary syndrome, and cardio-
vascular disease), RBP-4 concentration has been shown to
be elevated [106, 124–128]. Other studies have reported low
levels of the protein in humans with T2DM and have deter-
mined that RBP-4 concentration does not relate to insulin
sensitivity in calorie restricted obese individuals [129–131].
It has moreover been demonstrated that overexpression of
RBP-4 in normal mice increases insulin resistance, whereas4 International Journal of Endocrinology
genetic disruption of this adipokine increases insulin sensi-
tivity [123].
In normal pregnancy, RBP-4 increases signiﬁcantly
between early and late pregnancy with a parallel decrease
in insulin sensitivity [132], although other authors have
reported a decrease in the levels of this hormone after early
gestation [133].
GDM has been associated with increased, decreased, or
even stable levels of RBP-4 [134–138]. In pGDM it has been
shown that RBP-4 was signiﬁcantly higher more than 18
months postpartum in women with normal or impaired
glucosetoleranceorwithdiabetesmellitusinthepostpartum
period compared with women without GDM. A trend was
also documented of increasing RBP-4 values from normality
to DM in the pGDM group (P for linearity = 0.006).
Furthermore, RBP-4 was positively correlated with fasting
insulin, whereas the correlation to adiponectin was negative.
Finally, RBP-4 concentration was signiﬁcantly higher in
womenwithmetabolicsyndromethaninthosewithout[91].
Another study [92]t h a tm e a s u r e dR P B - 4l e v e l si n6 0
women with GDM during pregnancy as well as 6 weeks
and 6 months after delivery found a positive correlation
of RBP-4 with fasting insulin levels. Additionally, there
was a signiﬁcant reduction in RBP-4 in the control group
between delivery and 6 weeks and 6 months postpartum,
although there was no respective decrease in the GDM
group.Betweenthetwogroups,asigniﬁcantdiﬀerenceinthe
levels of RBP-4 (P<0.05) was not observed until 6 weeks
postpartum.
2.4. Resistin. Resistin, a hormone expressed by adipocytes as
well as monocytes and macrophages [107], appears to have
levels that parallel the mass of adipose tissue [107–109]. In
obesity and insulin resistance, the role of resistin is as yet
highly controversial [110, 111], although its function has
been associated with impaired glucose tolerance [106, 111].
The results in animal experiments are indicative of insulin
resistance induction in animals, but the same is not true in
humans [107, 111–113].
In normal pregnancy it is expressed in human placenta
[114], with plasma resistin levels in pregnant women being
signiﬁcantly higher as compared to normal controls. It
increases in the third trimester [68, 76, 114–116]a n dm a y
regulate energy metabolism during pregnancy.
In GDM its levels have been found either elevated or
decreased [76, 117–120], with some studies having reported
elevated maternal resistin in GDM [68, 118, 121, 147], while
others found lower [73, 118] or unaltered values [70].
With regard to pGDM, one study [91] showed that
resistin was signiﬁcantly higher 18 months postpartum in
women with normal or impaired glucose tolerance who
h a dp G D Mc o m p a r e dt oag r o u po fw o m e nw h od i dn o t
develop DM during pregnancy. This could be explained by
a biphasic eﬀect of insulin on the release of resistin, whereby
low concentration of insulin increases the release of resistin,
whilethisisreducedathigherinsulinlevels[76].Theauthors
also reported that plasma resistin levels correlated with BMI,
fat quantity, and plasma insulin and that the presence of
metabolic syndrome was not signiﬁcantly associated with
plasma resistin levels in the postpartum period.
2.5. Visfatin. Visfatin is an adipocytokine produced mainly
in visceral fat, as compared to subcutaneous fat, which exerts
insulin mimetic action [139] and, additionally, plays a pro-
inﬂammatory role [140].
It has higher concentrations in cases of obesity or insulin
resistance, including T2DM and metabolic syndrome [139,
141, 142]. Conversely, other studies showed no relation of
visfatin to insulin sensitivity or increased BMI and visceral
fat mass [143, 144].
In pregnancy, although this hormone has been reported
by some authors to maintain the same levels in the third
trimester as in the non-pregnant state [145], other studies
have demonstrated an increase [72, 146]. Visfatin levels peak
between 19 and 26 weeks of gestation, while at between 27
and 34 weeks visfatin has the lowest serum concentrations
[147].
Morgan et al. reported that visfatin may have a paracrine
or autocrine action since it is locally increased in omental fat
without increased plasma levels in pregnancy [148].
Some studies have shown elevated levels in women with
GDM [149–151] with a further increase of these levels
detected in the presence of high maternal blood glucose
levels. In contrast, a number of other studies found that
visfatin levels are lower in GDM [146, 152–154]. Figure 1
displays aspects of the aforementioned adipokines.
3. Other Mediatorsof InﬂammationinpGDM
3.1. TNF-α and IL-6. TNF-α and IL-6 are inﬂammatory
mediators produced by monocytes and macrophages in the
adipose tissue. These cytokines are increased in obesity
and have multiple eﬀects on insulin sensitivity in muscles,
liver, or beta cells of the pancreas, ultimately leading to
insulin resistance [32, 168]. In pregnancy, TNF-α and IL-
6p r o d u c t i o no c c u r si np l a c e n t a[ 163, 164], while it is
considered that a chronic inﬂammatory process in the
adipose tissue may contribute to pregnancy-induced insulin
resistance [164–167, 169]. Placental production of TNF has
been shown to be maximized late in pregnancy [163]a n dt o
declinerapidlyafterpregnancy,thisbeinginaccordancewith
placental production of TNF-α [155]. In early pregnancy
TNF-α mRNA is present mainly in syncytiotrophblast. Later
in pregnancy and speciﬁcally near term, TNF-α mRNA also
appears in villous stromal cells and TNF-α transcripts are
present in maternal cells in the decidua adjacent to the
extracellularmembranes[164].MostoftheTNF-αproduced
by the placenta is delivered to maternal circulation and by
comparison only a small amount to the fetal compartment
[164].
Though in a GDM pregnancy IL-6 and TNF-α rarely
increase [165–167], when this does occur, the increase
is caused by the oxidative stress and the inﬂammation
associated with the hyperglycemia [169]. Conversely, TNF-
α possibly inhibits insulin secretion and insulin regulated






Adiponectin Adipokines in GDM and pGDM
Figure 1: Molecular structure of the main adipokines produced by adipose tissue in GDM and pGDM. Adiponectin is a 244-amino-acid
polypeptide that decreases as adipose tissue increases; it enhances insulin action and is decreased in pGDM and GDM. Leptin is a 167-
amino-acid protein; it causes insulin action to increase and its levels show variability with respect to GDM and pGDM. Resistin (or adipose
tissue-speciﬁc secretory factor) has 108 amino acids in the prepeptide form; its action on insulin has yet to be clariﬁed. RBP-4 is a 183-
amino-acid protein which reduces insulin action. Both resistin and RBP-4 levels appear increased, decreased, or unaltered in GDM but are
uniformly increased in pGDM. The visfatin molecule consists of 491 amino acids; it facilitates insulin action and increases in GDM, while
its actions in pGDM need further clariﬁcation.
experiment showed that placentas from women with GDM
released more TNF-α in response to a glucose stimulus than
placentas from women with normal glucose tolerance [156].
IL-6 levels are signiﬁcantly higher in women with pGDM
at least 1 year postdelivery (mean 4 years postpartum) com-
p a r e dw i t hn o r m a lc o n t r o l s[ 98], this diﬀerence becoming
nonsigniﬁcant when it was adjusted for BMI. It is interesting
to note that when nonobese women with pGDM were
examined, the diﬀerence remained signiﬁcant for IL-6 (BMI
played no role) and that IL-6 was positively related to CRP,
this persisting even after adjustment for BMI.
TNF-αwasnotsigniﬁcantlydiﬀerentinpGDM3months
after delivery compared to women with normal glucose
tolerance during pregnancy [43]. By contrast, IL-6 was
signiﬁcantly higher before adjusting for BFM but after
adjustment for BFM adiponectin did not correlate to IL-6.
Hauguel-de Mouzon et al. reported in a recent study that
TNF-α rose signiﬁcantly 6 weeks postpartum both in women
with normal pregnancies and in GDM pregnancies when
comparedtoantepartumvalues[100].TheincreaseforTNF-
α was not signiﬁcant for both groups 6 months postpartum.
In another study, 18 women with pGDM at least 12
months after delivery were compared with normal con-
trols and women with polycystic ovary syndrome (PCOS).
They found no signiﬁcant diﬀerence in TNF-α between the
pGDM cases and controls, although the diﬀerence between
PCOS and controls was signiﬁcant [157].
3.2. C-Reactive Protein. CRP, an inﬂammatory agent com-
moninnumerouspathologicconditions,hasbeenassociated
with metabolic abnormal states such as insulin resistance,
hyperglycemia, and T2DM [31, 34–36], while it also appears
to be associated with central obesity [44, 46].
In the ﬁrst trimester of pregnancy the levels of CRP are
increased and have been related to higher risk for GDM
development[156,157],thisassociationalsobeingvalidwith
measurement of CRP later in the course of pregnancy [160,
170]. Furthermore, CRP is increased in maternal obesity,
insulin resistance, and maternal dysglycemia [158, 161, 162].
The pathophysiologic role of inﬂammatory proteins and
adiponectin seem to be the gradual impairment of beta
cell function and increasing insulin resistance, which results
in ineﬀective plasma glucose regulation and subsequent
dysglycemia in the months and years that follow pregnancy.
As concerns pGDM, there is some evidence that women
with a history of prior GDM have postpartum increased
CRP that manifests chronic subclinical inﬂammation [40–
46]. Increased CRP levels in women with pGDM, which have6 International Journal of Endocrinology
also been related to metabolic syndrome [45], have been re-
ported in several studies [43–46].
The postpartum period which is complicated by gesta-
tional diabetes is a period of chronic subclinical inﬂamma-
tion. Some investigators have shown signiﬁcantly increased
levels of CRP 3 months after delivery in women with pGDM
compared with controls [43]. Other authors also found a
negativecorrelationbetweenadiponectinlevelsandCRP,but
this correlation became nonsigniﬁcant after adjustment for
BFM, the latter being explained by the ﬁnding that CRP
is also related to central obesity [44, 46]. The NHANES
III study showed that adjustment of CRP values for waist
circumference attenuated diﬀerences in women with pGDM
and normal women [171].
Another study [172] recruiting 46 women with pGDM
3 years postpartum reported that women with pGDM had
signiﬁcantly elevated high-sensitivity CRP (hs-CRP) com-
pared with controls.
Heitritter et al. [90] studied 25 women with pGDM and
found that in a mean period of 4 years postpartum they had
signiﬁcantly higher CRP levels compared to controls. The
diﬀerence remained signiﬁcant after adjustment for BMI.
CRP was negatively related to adiponectin and positively
related to IL-6 and these associations remained unchanged
after adjustment for BMI.
In another study, 18 women with pGDM at least 12
monthsafterindexdeliverywerefoundtohavenosigniﬁcant
diﬀerence in hs-CRP compared with normal controls [157].
On the other hand, other authors [46] studied 70
women with pGDM 6 years after their pregnancy and found
signiﬁcantly higher CRP levels in women with pGDM in the
presence of abdominal obesity; they also found abnormal
glucose tolerance compared with the women without a
history of GDM. This was further conﬁrmed in another
study where signiﬁcantly elevated CRP levels and ﬁbrinogen
were detected in 26 women with pGDM as compared with
controls [44].
3.3. Plasminogen Activator Inhibitor 1. Plasminogen Activa-
tor Inhibitor 1 (PAI-1) is a protein that in humans is en-
coded by the SERPINE1 gene and is mainly produced by the
endothelial cells, though it is also secreted by other tissue
types, such as adipose tissue. Its main function is to inhibit
tissue plasminogen activator (tPA) and urokinase (uPA),
the activators of plasminogen, and hence ﬁbrinolysis. PAI-
1 is increased in various disease states, such as obesity, MS,
insulin resistance, and T2DM [31, 34–36].
PAI-1 is increased in women with pGDM compared
with normal women 3 months after delivery [43]. In this
study PAI-1 remained higher after adjustment for BFM,
while the authors also found a negative correlation between
adiponectin levels and PAI-1.
Another study [172] reported that women with pGDM
had signiﬁcantly elevated PAI-1 compared with controls 3
years after delivery.
Otherauthorsstudying 74womenwithpGDM3months
after delivery found them to exhibit increased PAI-1 levels
when they had impaired insulin sensitivity postpartum,
while tPA was also observed to be elevated [42]. In another
study, 25 women with pGDM demonstrated signiﬁcantly
h i g h e rP A I - 1l e v e l sc o m p a r e dt oc o n t r o l si nam e a np e r i o d
of 4 years postpartum [98], although the diﬀerence lost sig-
niﬁcance after adjustment for BMI. Meanwhile, adiponectin
levels correlated to PAI-1 levels before and after adjustment
for BMI.
4. Conclusions
Women with pGDM are characterized by chronic subclinical
inﬂammation which is associated with insulin resistance and
abnormality in glucose metabolism. Approximately 30% of
these women have metabolic syndrome and many of them
will develop T2DM within 5 years of diagnosis [26, 31, 173].
The conversion rates from GDM to T2DM range from 2.6%
to 70% over a period of 6 weeks to 28 years postpartum
[174].Theproblemofgestationaldiabetesiscommonandits
incidence is exhibiting an increasing prevalence. Early recog-
nition and management of women predisposed to develop
T2DM later in their lives is thus crucial in the development
of primary health care strategies, modiﬁcation of lifestyle,
and dietary habits signiﬁcantly enabling prevention or delay
of appearance of glucose intolerance states in predisposed
women.
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